May 2023 in “International Journal of Trichology” Tofacitinib effectively treated severe hair loss in a patient who didn't respond to other treatments.
April 2023 in “International Journal of Research in Dermatology” Baricitinib is a promising treatment for severe alopecia areata with minimal side effects.
April 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” Intravenous methylprednisolone helped over half of alopecia areata patients regrow hair, but many relapsed.
April 2023 in “Journal of Pakistan Medical Association” Baricitinib is effective in promoting hair growth in severe alopecia areata.
January 2023 in “Rossijskij žurnal kožnyh i veneričeskih boleznej” New treatments for child hair loss due to immune issues are effective but not yet officially approved.
January 2023 in “National Journal of Physiology, Pharmacy and Pharmacology” Tofacitinib effectively reduced hair loss in alopecia areata patients without adverse effects.
October 2022 in “Journal of Armed Forces Medical College, Bangladesh” Tofacitinib is effective and safe for treating alopecia areata.
September 2022 in “Journal of The American Academy of Dermatology” Baricitinib was effective in regrowing eyebrow and eyelash hair in patients with severe alopecia areata.
Hair loss can be caused by hormones, illness, autoimmune disorders, or vitamin deficiencies, and treatments vary depending on the type.
June 2022 in “Value in Health” Adding Baricitinib for severe alopecia areata will have a small impact on a health plan's budget.
March 2022 in “JAMA Dermatology” In 2021, JAMA Dermatology published significant findings on skin conditions post-COVID vaccination, melanoma surveillance, atopic dermatitis treatments, and confirmed that sun protection does not harm bone health.
March 2022 in “Wound practice & research” New treatments for alopecia areata show promise, but standardized guidelines are needed.
January 2022 in “Clinical Cases in Dermatology” A 22-year-old man has alopecia areata, an autoimmune hair loss condition, with various treatments available.
December 2021 in “Journal of The American Academy of Dermatology” COVID-19 can cause different types of hair loss, which may last up to 100 days, and treatments are still being explored.
October 2021 in “Dermatology Reports” Tofacitinib, a hair regrowth treatment, may worsen acne.
October 2021 in “Journal of the European Academy of Dermatology and Venereology” There have been major advances in diagnosing and treating hair loss over the last 30 years, with new drugs and improved hair transplant techniques.
September 2021 in “Journal of the Dermatology Nurses' Association” The convention discussed various skin conditions, treatments, and the importance of continuous learning in dermatology nursing.
January 2021 in “Anais do Congresso Brasileiro de Reumatologia 2020” Tofacitinib improved arthritis and partially improved hair loss in a lupus patient without side effects.
November 2020 in “Dubai medical journal” Tofacitinib may effectively regrow hair in alopecia totalis patients.
August 2020 in “Ugeskrift for Læger” A man with severe hair loss regrew all his hair using tofacitinib and stayed healthy for a year.
January 2019 in “Springer eBooks” Combination therapies might work better for some vitiligo patients, but results vary.
January 2018 in “Journal of the American Academy of Dermatology” Combining pulsed prednisone with tofacitinib can lead to lasting hair regrowth in severe alopecia areata patients.
December 2017 in “Actas dermo-sifiliográficas/Actas dermo-sifiliográficas” JAK inhibitors show promise for treating Alopecia Areata, while statins are not recommended.
August 2017 in “Journal of biotechnology” Topical corticosteroids are the best initial treatment for children with Alopecia Areata.
June 2017 in “Journal of the American Academy of Dermatology” Tofacitinib is effective and safe for treating severe alopecia areata and related conditions.
April 2017 in “Leukemia research” Tofacitinib helped most teenagers in the study regrow hair with mild side effects.
January 2016 in “Chemistry & Industry” Two drugs, tofacitinib and ruxolitinib, may help regrow hair by activating hair follicles.
May 2011 in “Value in Health” CP-690,550 significantly reduced itching in patients with moderate-to-severe plaque psoriasis.
February 2011 in “Annales de dermatologie et de vénéréologie” Tofacitinib shows promise for treating severe alopecia areata with good safety and effectiveness.
5 citations,
January 2021 in “Inflammatory Bowel Diseases” Tofacitinib improved ulcerative colitis, skin ulcers, and hair loss in a patient who didn't respond well to other treatments.